The India active pharmaceutical ingredients market is projected to register a CAGR of 7.46% during 2027–2032, supported by domestic manufacturing investments, contract production, and growing demand for specialized pharmaceutical ingredients.
Hyderabad, India, Nov. 04, 2026 (GLOBE NEWSWIRE) -- According to a recent report by Mordor Intelligence, the India active pharmaceutical ingredients (API) market size was valued at USD 15.28 billion in 2026 and is estimated to grow from USD 16.46 billion in 2027 to reach USD 23.59 billion by 2032, at a CAGR of 7.46% during the forecast period (2027–2032). The market is benefiting from government initiatives to strengthen domestic pharmaceutical manufacturing, increasing demand for specialized APIs, and the expansion of contract development and manufacturing capabilities. Pharmaceutical companies are also focusing on backward integration and supplier diversification to reduce exposure to imported raw materials. Investments in biologics, high-potency ingredients, and shared manufacturing infrastructure are creating additional opportunities for Indian producers. However, input-cost volatility, regulatory compliance expenses, and the capital requirements associated with specialized manufacturing continue to influence market development.
India Active Pharmaceutical Ingredients Market Geographic Outlook
India's API manufacturing landscape is supported by established pharmaceutical production clusters and emerging industrial infrastructure across several states. Andhra Pradesh and Telangana have developed manufacturing capabilities around Visakhapatnam and Hyderabad, including commercial API production and specialized facilities for complex molecules. Gujarat remains an important manufacturing location, with API producers and the development of shared infrastructure at Jambusar. Himachal Pradesh is also attracting investment through the development of the Haroli Bulk Drug Park, which is intended to provide common utilities and infrastructure for pharmaceutical manufacturers.
These locations contribute to India's ability to serve domestic formulation companies and international pharmaceutical customers. However, the report does not provide individual state-level market shares or regional CAGRs, so the geographic outlook is based on manufacturing activity and infrastructure developments rather than a numerical regional ranking.
"India’s API market is benefiting from investments in domestic manufacturing, backward integration, and specialized production capabilities. As pharmaceutical companies diversify sourcing strategies and expand contract manufacturing partnerships, suppliers with reliable quality systems and scalable operations are well positioned to capture emerging opportunities," says Soumya Goud, Senior Research Manager at Mordor Intelligence.
India Active Pharmaceutical Ingredients Market Trends & Forecast
Domestic Sourcing Strategies Reshape Pharmaceutical Supply Networks
Pharmaceutical manufacturers are increasingly evaluating domestic sourcing options for APIs, key starting materials, and intermediates. Exposure to imported pharmaceutical inputs has encouraged producers to strengthen backward integration and consider alternative suppliers. Government production-linked incentive schemes and bulk-drug manufacturing initiatives are supporting this transition by encouraging domestic capacity development. For API manufacturers, the opportunity lies in converting policy support and new production infrastructure into commercially qualified supply relationships with formulation companies.
Specialized Molecule Production Creates New Contract Manufacturing Opportunities
Demand for oncology medicines, biologics, and other specialized therapies is increasing the importance of manufacturing capabilities that require dedicated facilities and technical expertise. High-potency API production, peptide manufacturing, and biologic drug-substance capabilities are creating opportunities for companies with specialized infrastructure. Contract manufacturers can benefit by offering pharmaceutical and biotechnology companies access to these capabilities without requiring customers to establish their own production facilities. Successful commercialization, however, depends on process validation, quality qualification, and the ability to meet customer-specific requirements.
Shared Industrial Infrastructure Influences the Economics of API Expansion
The development of bulk-drug parks is creating opportunities to reduce infrastructure duplication for pharmaceutical manufacturers. Common facilities for water supply, effluent treatment, solvent recovery, and waste management can support the establishment of new API production units. Such infrastructure is particularly relevant for manufacturers evaluating capital-intensive projects or expanding into additional production locations. The commercial impact will depend on the timely completion of shared utilities, regulatory clearances, and the ability of individual facilities to move from construction to qualified manufacturing operations.
India Active Pharmaceutical Ingredients Market Segmentation Overview
The India active pharmaceutical ingredients market is segmented by business model, synthesis type, molecule size, potency, therapeutic area, and end user.
By Business Model
- Captive API
- Merchant / Contract API
By Synthesis Type
- Synthetic API
- Biotech API
By Molecule Size
- Small-Molecule API
- Large-Molecule / Biologic API
By Potency
- High-Potency API
- Low / Medium-Potency API
By Therapeutic Area
- Cardiovascular
- Oncology
- Infectious Diseases
- Metabolic Disorders
- CNS and Neurology
- Respiratory
- Others
By End User
- Pharma and Biopharma Companies
- CDMOs / CMOs
- CROs and Academia
- Export-Oriented Formulators
- CRDMOs / CDMOs
For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: https://www.mordorintelligence.com/industry-reports/india-active-pharmaceutical-ingredients-market?utm_source=globenewswire
India Active Pharmaceutical Ingredients Market Competitive Outlook
The India API market features established pharmaceutical manufacturers, specialized API producers, and contract development and manufacturing organizations. Competition is influenced by production scale, backward integration, manufacturing quality, technical expertise, and the ability to serve both captive and external customers. Companies with diversified API portfolios and established manufacturing infrastructure are positioned to serve a broad range of pharmaceutical requirements, while specialized producers are developing capabilities in biologics, oncology ingredients, and high-potency compounds.
Market participants are investing in manufacturing expansion, process development, and contract production capabilities to strengthen their positions. The growing importance of merchant and contract APIs is creating opportunities for companies that can support customers from early-stage development through commercial manufacturing. At the same time, input-cost volatility and increasingly demanding quality requirements are placing greater emphasis on operational efficiency, supplier reliability, and regulatory compliance.
India Active Pharmaceutical Ingredients Industry Leaders
- Lupin Ltd.
- Aurobindo Pharma Ltd.
- Viatris India (Agila)
- Divi's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
Explore Trending Reports from Mordor Intelligence
The Pharmaceutical Analytical Testing Outsourcing Market is expected to grow from USD 10.27 billion in 2026 to USD 15.09 billion by 2031, registering a CAGR of 8.00%, supported by increasing pharmaceutical R&D activity, rising outsourcing of quality control and testing services, and growing regulatory requirements for drug safety and efficacy.
The Surgical Instrument Tracking Market is projected to expand from USD 362.64 million in 2026 to USD 673.42 million by 2031, at a CAGR of 13.18%, driven by the need to improve surgical instrument traceability, strengthen infection prevention, reduce instrument losses, and enhance operating room efficiency.
The Ear Infection Treatment Market is expected to grow from USD 14.07 billion in 2027 to USD 17.98 billion by 2032, registering a CAGR of 5.05%, supported by the rising prevalence of ear infections, increasing demand for effective treatment options, and greater awareness of early diagnosis and management.
The Preoperative Surgical Planning Software Market is projected to increase from USD 126.66 million in 2026 to USD 177.68 million by 2031, at a CAGR of 7.01%, driven by growing adoption of digital surgical workflows, increasing use of 3D visualization and patient-specific planning, and demand for improved surgical precision.
The Parenteral Nutrition Market is expected to grow from USD 8.99 billion in 2026 to USD 11.94 billion by 2031, registering a CAGR of 5.82%, supported by rising demand for nutritional support among patients unable to meet their needs through oral or enteral feeding, increasing hospital admissions, and growing prevalence of chronic and critical illnesses.
About Mordor Intelligence
Mordor Intelligence is a global market intelligence firm, founded in 2014, helping businesses make informed decisions through data-driven insights, industry expertise, and advanced analytics. With 550+ domain experts and on-ground specialists across 180+ countries, the company delivers comprehensive intelligence across aerospace & defense, agriculture, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, and logistics.
Its offerings include syndicated industry reports, custom research and advisory, and subscription platforms such as Synapse, Data Center Intelligence, and Robotics Intelligence. Mordor Intelligence is ISO 9001:2015 and ISO/IEC 27001:2022 certified, a member of ESOMAR and the Market Research Society of India, and a four-time Great Place to Work® honoree. Learn more at mordorintelligence.com.
CONTACT: For any inquiries or to access the full report, please contact: media@mordorintelligence.com https://www.mordorintelligence.com
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!